Stephen Farrelly
Stephen Farrelly is the global head of pharma and healthcare at ING, where he analyzes market trends and their implications for consumers. He has highlighted that the imposition of tariffs on generic drugs could significantly increase costs for consumers, particularly those without insurance, who would be hit hardest by rising drug prices resulting from these tariffs.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Taiwan | 1 | 5.00 | 0.13% | +0% | 23,816,775 | 31,587 | $670,000 | 889$ |
| Totals | 1 | 23,816,775 | 31,587 | $670,000 | 889$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Taiwan:
Stephen Farrelly is the ING global pharma and healthcare lead who expressed concerns about the potential drag on the vaccine sector.
5
United States:
Stephen Farrelly, ING’s global health care sector lead, explained the complexities of drug pricing in the US.
5
United Kingdom:
Stephen Farrelly, global lead for pharma and healthcare at ING, says tariff threats have been a catalyst for pharmaceutical firms.
5
Ireland:
Stephen Farrelly, global head of pharma and healthcare at ING, said the people who would be 'hardest hit' were those without insurance.
6